



IFM

Atty. Dkt. No. 065691-0440

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Alain MOUSSY et al.
Title: 2-AMINOARYLOXAZOLE
COMPOUNDS AS TYROSINE
KINASE INHIBITORS
Appl. No.: 10/576,267
International Filing Date: 10/22/2004
371(c) Date: 4/23/06
Examiner: Unassigned
Art Unit: 1614
Confirmation Number: 4376

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT


All of the documents are in English.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

Date 17-AUG-2007

By 

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 295-4059
Facsimile: (202) 672-5399

Rouget F. Henschel
Attorney for Applicant
Registration No. 39,221

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: <i>(use as many sheets as necessary)</i>				Complete if Known		
Application Number				10/576,267		
Filing Date				10/22/2004		
First Named Inventor				Alain MOUSSY		
Art Unit				1614		
Examiner Name				Unassigned		
Attorney Docket Number				065691-0440		

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/G.S./	A1	5,000,775 A	03-19-1991	Grabiak et al.	

Examiner Initials*	Cite No. ¹	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code ² (if known)			

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
/G.S./	A2	WO 2005/000298 A2	01-06-2005	Triad Therapeutics, Inc.		
	A3	WO 2004/032882 A2	04-22-2004	Smithkline Beecham Corporation		
	A4	WO 2004/001059 A2	12-31-2003	Bristol-Myers Squibb Company		
	A5	WO 02/45652 A2	06-13-2002	Merck & Co., Inc.		
	A6	EP 0 949 242 A1	10-13-1999	Chugai Seiyaku Kabushiki Kaisha		
	A7	EP 0 254 259 A2	01-27-1988	Otsuka Pharmaceutical Factory, Inc.		

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
/G.S./	A8	MURALI et al., "A Modified Approach to 2-(N-Aryl)-1,3-oxazoles", <i>Organic Letters</i> , Vol. 4, No. 12, 2002, pp. 2091-2093.	
↓	A9	NATH et al., "Synthesis and Mercuration of Some New 2-arylamino-4,5-disubstituted Oxazoles as Pesticides", <i>Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry</i> , Vol. 20(B), No. 9, 1981, pp. 827-829.	
	A10	RAO et al., "Synthesis and fungitoxicity of substituted pyrazolyloxazole", <i>Journal of the Indian Chemical Society</i> , Vol. 58, No. 9, 1981, pp. 925-926.	

Examiner Signature	/Golam Shameem/	Date Considered	02/02/2009
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LISTED OTHERWISE